Disclaimer
The assessment made available on the Rejuve website does not create a doctor-patient relationship between the individual completing the assessment and Rejuve. All medical services are provided exclusively by OpenLoop Health, a network of U.S.-licensed doctors and clinicians that follow rigorous medical protocols designed for patient safety. OpenLoop Health has established exclusionary criteria to determine whether an individual qualifies for GLP-1 treatment. The answers provided in the Rejuve assessment determine if an individual may be screened out of eligibility, and an OpenLoop Health clinician will meet with the individual after checkout to determine whether a prescription is appropriate. OpenLoop Health clinicians retain full discretion to prescribe compounded GLP-1 medications to patients.
All claims and benefits described on this website are based on self-reported data from patients enrolled in treatment plans that include compounded GLP-1 medications and telehealth consultations with OpenLoop medical professionals. Patients reported their weight on their initial intake and approximately every 3–4 weeks thereafter. Results with compounded medications obtained through OpenLoop may vary based on individual adherence to the program, lifestyle factors, and the clinician’s medical judgment. Compounded GLP-1s are produced in FDA-registered outsourcing facilities; however, compounded medications are not FDA-approved or evaluated for safety, efficacy, or quality. The decision to prescribe compounded drugs is made solely by the OpenLoop licensed provider after a telehealth consultation and review of medical history.
We encourage all prospective patients to discuss the risks and benefits of compounded medications with their OpenLoop provider. Rejuve does not manufacture medications. The medication dispensed may look different from images shown on the Rejuve website.
Pharmacy Providers
All prescriptions from OpenLoop Health are fulfilled through its partnered U.S.-based, licensed pharmacies. OpenLoop maintains oversight of pharmacy relationships, including monitoring product sourcing, availability, and quality reports.
Additional Notes
Results vary depending on starting weight, adherence to the program, and lifestyle changes.
Reported inches lost from hips, waist, chest, thighs, and arms are not typical and may not represent average results.
Medication prescriptions are at the discretion of OpenLoop medical providers and may not be suitable for everyone.
Patients typically report losing 1–2 lbs per week after 4 weeks when combined with healthy diet and exercise changes.
Consult a healthcare professional before starting any medication or weight loss program.
Medication is included in the cost of the Rejuve Program. Wegovy® is FDA-approved for weight loss. Ozempic® is FDA-approved for type 2 diabetes treatment but may be prescribed off-label for weight loss. The trademarks, service marks, and trade names (Wegovy®, Ozempic®) are the property of their respective owners. All medical treatment available through Rejuve is provided exclusively by OpenLoop Health and its affiliated professional corporations. No data, photos, claims, or other information presented on this website is derived from clinical trials or public studies—it reflects only Rejuve patient experience.
